The FDA has approved the complement C3 inhibitor pegcetacoplan (Syfovre – Apellis) for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Given as a series of monthly or every-other-month (EOM) intravitreal injections, it is the first drug to become available for use in patients with atrophic dry AMD. Subcutaneous pegcetacoplan was approved earlier as Empaveli for treatment of paroxysmal nocturnal hemoglobinuria.
AGE-RELATED MACULAR DEGENERATION ― AMD has two major forms. The dry (non-neovascular) form occurs in about 90% of patients and is...
- Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)
- In Brief: Rezvoglar - Another Insulin Glargine Product Interchangeable with Lantus
- Atezolizumab (Tecentriq) for Alveolar Soft Part Sarcoma (online only)
- Olutasidenib (Rezlidhia) for Acute Myeloid Leukemia (online only)
- In Brief: Fam-trastuzumab deruxtecan (Enhertu) for Breast Cancer (online only)
RELEASE
The Vibrant orally administered vibrating capsule (Vibrant Gastro), an FDA-cleared medical device, is now available by prescription for treatment of adults with chronic idiopathic constipation (CIC) who have not experienced relief of their bowel symptoms by using laxative therapies at the recommended dosage for at least one month. It is the first drug-free treatment to be authorized by the FDA for this indication.
CHRONIC IDIOPATHIC CONSTIPATION — CIC …